RESUMO
PURPOSE: To compare retrospectively the safety and efficacy of yttrium-90 ((90)Y) radioembolization with the safety and efficacy of chemoembolization in patients with unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Survival and complication rates were evaluated for patients with HCC who underwent chemoembolization or radioembolization at a single institution between August 2007 and April 2010. Complications were graded according to a standardized grading system for embolization procedures. Survival was determined via the Kaplan-Meier method, and multivariable analysis for factors affecting survival was performed. RESULTS: This study included 73 patients with HCC who underwent index embolization with radioembolization (n = 38; 52.1%) or chemoembolization (n = 35; 47.9%). The two patient populations were similar in terms of demographics, etiology of cirrhosis, functional status, tumor characteristics, Child-Pugh class, previous liver-directed therapy, and number of patients with bilirubin > 2.0 mg/dL. There was no significant difference in survival between the radioembolization (median 8.0 months) and chemoembolization (median 10.3 months) cohorts (P = .33). Postembolization syndrome was significantly more severe in patients who underwent chemoembolization, which led to increased total hospitalization rates in these patients. The rates of other complications and rehospitalization were similar between groups. Increased age, Child-Pugh class B, hepatitis seropositivity, bilobar tumor distribution, tumor vascular invasion, and presence of extrahepatic metastases were associated with reduced patient survival. CONCLUSIONS: Patients treated with radioembolization did not show a survival advantage over patients treated with chemoembolization. However, patients who underwent chemoembolization had significantly higher rates of hospitalization as a result of postembolization syndrome.
Assuntos
Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica/mortalidade , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/mortalidade , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/terapia , Radioterapia/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Comorbidade , Feminino , Hepatectomia/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Lesões por Radiação/mortalidade , Compostos Radiofarmacêuticos/uso terapêutico , Medição de Risco , Fatores de Risco , Análise de Sobrevida , Taxa de Sobrevida , Resultado do Tratamento , Estados Unidos/epidemiologia , Radioisótopos de Ítrio/uso terapêuticoRESUMO
BACKGROUND: Bone-seeking radiopharmaceuticals can deposit radiation selectively to some osteosarcoma tumours because of the bone-forming nature of this cancer. OBJECTIVES: This is the first report of using 223-radium, an alpha-emitting calcium analogue with a high therapeutic index, in combination therapy with other agents in 15 patients with metastatic osteoblastic osteosarcoma. METHODS: Candidates for alpha-radiotherapy if 99mTc-MDP bone scan had avid bone-forming lesions and no therapy of higher priority (eg, definitive surgery). Monthly 223-radium infusions (1.49 µCi/kg or 55.13 kBq/kg) were given. RESULTS: The median infusion number was three and the average time to progression was 4.3 months for this cohort receiving 223-radium+other agents. Agents provided during 223-radium included (1) drugs to reduce skeletal complications: monthly denosumab (n=13) or zolendronate (n=1); (2) agents with antivascular endothelial growth factor activity, pazopanib (n=8) or sorafenib (n=1), (3) alkylating agents: oral cyclophosphamide (n=1) or ifosfamide, given as a 14-day continuous infusion (n=1, two cycles), (4) high-dose methotrexate (n=1), pegylated liposomal doxorubicin (n=1); and (5) two other combinations: nivolumab and everolimus (n=1) and rapamycin and auranofin (n=1). Radiation therapy, including stereotactic body radiotherapy (SBRT), was also given to 11 patients concurrently with 223-radium (n=2), after 223-radium completion (n=3), or both concurrently and then sequentially for other sites (n=6). After 223-radium infusions, patients without RT had a median overall survival of 4.3 months compared with those with SBRT and/or RT, who had a median overall survival of 13.5 months.Conclusion Although only 1/15 of patients with osteoblastic osteosarcoma still remain alive after 223-radium, overall survival.
Assuntos
Osteossarcoma/radioterapia , Radiocirurgia/métodos , Adolescente , Adulto , Criança , Progressão da Doença , Feminino , Humanos , Masculino , Metástase Neoplásica , Osteossarcoma/patologia , Rádio (Elemento) , Adulto JovemRESUMO
OBJECTIVE:: In acute gastrointestinal bleeding, despite positive dynamic phase 99mTc-red blood cell scintigraphy, invasive catheter angiography (CA) is frequently negative. In this study, we investigated the value of flow phase scintigraphy in predicting extravasation on CA. METHODS:: Institutional review board approval with a waiver of informed consent was obtained for this retrospective study. A total of 173 scintigraphy procedures performed in 145 patients with GIB between January 2013 and August 2014 were analysed. Scintigraphy had two phases: flow (1 image/s for 1 min) followed by dynamic (1 image/30 s for 1 h). Patients who underwent CA within 24 hours of positive scintigraphy were assessed. Each scintigraphy phase was randomly and independently reviewed by two nuclear medicine physicians blinded to the outcomes of the other phase and of CA. RESULTS:: A total of 42 patients (29%) had positive scintigraphy. Of these patients, 29 underwent CA, and extravasation was seen in 6 (21%). In all, dynamic phase scintigraphy was positive. 13 of the 29 patients also had positive flow phase scintigraphy. The sensitivity, specificity, positive-predictive value, and negative-predictive value of flow phase scintigraphy for extravasation on CA were 100, 70, 46, and 100%, respectively. Specificity and positive predictive value were higher when CA was performed within 4 hours of positive flow phase scintigraphy. CONCLUSIONS:: Negative flow phase scintigraphy can identify patients who will not benefit from CA despite positive dynamic phase scintigraphy. The likelihood of extravasation on CA is higher when performed soon after positive flow phase scintigraphy. ADVANCES IN KNOWLEDGE:: Negative flow phase scintigraphy identifies patients who will not benefit from invasive catheter angiography despite positive results on subsequent dynamic phase scintigraphy. Increasing the delay between positive red blood cell scintigraphy and catheter angiography progressively reduces the likelihood of identifying extravasation, which is required to target embolization.
Assuntos
Angiografia , Hemorragia Gastrointestinal/diagnóstico por imagem , Cintilografia/métodos , Compostos Radiofarmacêuticos , Tecnécio , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Eritrócitos , Extravasamento de Materiais Terapêuticos e Diagnósticos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Retrospectivos , Sensibilidade e Especificidade , Método Simples-Cego , Adulto JovemRESUMO
BACKGROUND: The purpose of this study was to compare the qualitative and quantitative assessment of perfusion on dual-energy CT (DECT) and planar and single photon emission computed tomography (SPECT)-CT V/Q scanning in patients with chronic thromboembolic pulmonary hypertension (CTEPH). METHODS: Nineteen patients with known CTEPH underwent both DECT and SPECT-CT V/Q scanning. Sixteen of these patients underwent planar V/Q imaging concurrently. Two readers independently graded DECT-perfused blood volume (PBV) defects on a four-point scale (0= normal, 1= mild <25%, 2= moderate 25-50%, 3= severe >50%). A grade was given for each lung lobe and for each of 18 lung segments. One reader graded the SPECT-CT images similarly. Quantitative measurements of lung perfusion were calculated with DECT and planar V/Q scanning for 16 of these patients. RESULTS: The inter-reader agreement on DECT was strong with agreement in 85% (258/304) of segments (kappa =0.86) and 84% (80/95) of lobes (kappa =0.82). The inter-modality agreement between DECT and SPECT-CT was lower. Readers 1 and 3 agreed in only 34% (103/304) of segments (kappa =0.25) and 33% (31/94) of lobes (kappa =0.22). Agreement between readers 2 and 3 was similar. Correlation between quantitative measurements with DECT and planar V/Q imaging was poor and ranged from 0.01 to 0.45. CONCLUSIONS: Inter-observer agreement in subjective grading of PBV maps is excellent. However, inter-modality agreement between DECT and SPECT-CT is modest. Automated quantification values of PBV maps correlate poorly with established tools like planar V/Q imaging. These differences need to be kept in mind during clinical decision making.
RESUMO
Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the potentially curable causes of pulmonary hypertension and is definitively treated with pulmonary thromboendartectomy. CTEPH can be overlooked, as its symptoms are nonspecific and can be mimicked by a wide range of diseases that can cause pulmonary hypertension. Early diagnosis of CTEPH and prompt evaluation for surgical candidacy are paramount factors in determining future outcomes. Imaging plays a central role in the diagnosis of CTEPH and patient selection for pulmonary thromboendartectomy and balloon pulmonary angioplasty. Currently, various imaging tools are used in concert, with techniques such as computed tomography (CT) and conventional pulmonary angiography providing detailed structural information, tests such as ventilation-perfusion (V/Q) scanning providing functional data, and magnetic resonance imaging providing a combination of morphologic and functional information. Emerging techniques such as dual-energy CT and single photon emission computed tomography-CT V/Q scanning promise to provide both anatomic and functional information in a single test and may change the way we image these patients in the near future. In this review, we discuss the roles of various imaging techniques and discuss their merits, limitations, and relative strengths in depicting the structural and functional changes of CTEPH. We also explore newer imaging techniques and the potential value they may offer.
Assuntos
Diagnóstico por Imagem/métodos , Hipertensão Pulmonar/diagnóstico por imagem , Embolia Pulmonar/diagnóstico por imagem , Doença Crônica , Humanos , Hipertensão Pulmonar/complicações , Hipertensão Pulmonar/fisiopatologia , Pulmão/diagnóstico por imagem , Pulmão/fisiopatologia , Embolia Pulmonar/complicações , Embolia Pulmonar/fisiopatologiaRESUMO
Esophageal cancer frequently causes a focal intense FDG uptake on positron emission tomography (PET) imaging while esophagitis often results in a mild to moderate degree of FDG activity in a diffuse pattern. However, detection of an esophageal cancer can become difficult in the presence of a diffuse esophageal activity because of esophagitis. We present such case in which esophageal cancer superimposed by Candidal esophagitis is difficult to recognize on FDG PET images.
Assuntos
Candidíase/complicações , Candidíase/diagnóstico por imagem , Neoplasias Esofágicas/complicações , Neoplasias Esofágicas/diagnóstico por imagem , Esofagite/complicações , Esofagite/diagnóstico por imagem , Fluordesoxiglucose F18 , Candidíase/metabolismo , Diagnóstico Diferencial , Neoplasias Esofágicas/metabolismo , Esofagite/metabolismo , Reações Falso-Negativas , Fluordesoxiglucose F18/farmacocinética , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons/métodos , Compostos Radiofarmacêuticos/farmacocinéticaRESUMO
PURPOSE: To propose a new method to estimate lung mean dose (LMD) using technetium-99m labeled macroaggregated albumin ((99m)Tc-MAA) single photon emission CT (SPECT)/CT for (90)Yttrium radioembolization of liver tumors and to compare the LMD estimated using SPECT/CT with clinical estimates of LMD using planar gamma scintigraphy (PS). METHODS AND MATERIALS: Images of 71 patients who had SPECT/CT and PS images of (99m)Tc-MAA acquired before TheraSphere radioembolization of liver cancer were analyzed retrospectively. LMD was calculated from the PS-based lung shunt assuming a lung mass of 1 kg and 50 Gy per GBq of injected activity shunted to the lung. For the SPECT/CT-based estimate, the LMD was calculated with the activity concentration and lung volume derived from SPECT/CT. The effect of attenuation correction and the patient's breathing on the calculated LMD was studied with the SPECT/CT. With these effects correctly taken into account in a more rigorous fashion, we compared the LMD calculated with SPECT/CT with the LMD calculated with PS. RESULTS: The mean dose to the central region of the lung leads to a more accurate estimate of LMD. Inclusion of the lung region around the diaphragm in the calculation leads to an overestimate of LMD due to the misregistration of the liver activity to the lung from the patient's breathing. LMD calculated based on PS is a poor predictor of the actual LMD. For the subpopulation with large lung shunt, the mean overestimation from the PS method for the lung shunt was 170%. CONCLUSIONS: A new method of calculating the LMD for TheraSphere and SIR-Spheres radioembolization of liver cancer based on (99m)Tc-MAA SPECT/CT is presented. The new method provides a more accurate estimate of radiation risk to the lungs. For patients with a large lung shunt calculated from PS, a recalculation of LMD based on SPECT/CT is recommended.
Assuntos
Braquiterapia/métodos , Neoplasias Hepáticas/radioterapia , Pulmão/diagnóstico por imagem , Pulmão/efeitos da radiação , Imagem Multimodal/métodos , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada por Raios X , Radioisótopos de Ítrio/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Hepatocelular/radioterapia , Carcinoma Hepatocelular/secundário , Embolização Terapêutica/métodos , Feminino , Humanos , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Movimento , Compostos Radiofarmacêuticos , Dosagem Radioterapêutica , Respiração , Estudos Retrospectivos , Agregado de Albumina Marcado com Tecnécio Tc 99mRESUMO
OBJECTIVE: Mantle cell lymphoma (MCL) is an aggressive type of non-Hodgkin lymphoma with a propensity for extranodal involvement. The role of fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging in common types of lymphoma has been well-established. However, there is limited information in the literature about the utility of FDG-PET imaging in patients who have MCL. The aim of this study was to determine the role of FDG-PET imaging in assessment of disease activity in MCL compared with conventional imaging techniques such as computerized tomography/magnetic resonance imaging (CT/MRI). METHODS: FDG-PET images of 20 patients with MCL who were referred to our center for assessment of extent of disease were reviewed retrospectively. The FDG-PET findings were compared with those of CT/MRI and were correlated with clinical information, histopathology, and outcome. RESULTS: The diagnostic sensitivity for PET was 90% (17/19), and specificity was 100% (1/1). For CT/MRI, the sensitivity was 87% (14/16) and specificity was 50% (2/4). PET was better than CT/MRI in detecting nodal involvement. With respect to extranodal involvement, PET detected more cases of spleen involvement than CT/MRI. PET was equivalent to conventional imaging in detecting bowel involvement. CONCLUSIONS: PET imaging has a high sensitivity in detecting both nodal and extranodal involvement in patients who have MCL. Based on the available data in patients who had other subtypes of non-Hodgkin lymphoma, the specificity of PET also appears to be superior to anatomic imaging techniques. FDG-PET imaging may prove to be the single most effective method for detection.